Novo Nordisk Reports Better Weight Loss Results for Experimental Obesity Drug CagriSema Compared to Eli Lilly’s Zepbound
Novo Nordisk announced that its experimental once-weekly obesity treatment, CagriSema (a combination of cagrilintide and semaglutide), outperformed a 5 mg dose of Eli Lilly's Wegovy in a phase 3 trial. The results showed greater weight loss for patients using Novo Nordisk’s drug compared to the competitor product. The findings highlight Novo Nordisk’s continued leadership in obesity treatments, with CagriSema representing an innovative combination therapy approach that could expand its market share and influence within this competitive sector of pharmaceuticals. The results may also impact investor sentiment toward both companies as they continue to develop GLP-1-based therapies for weight management. Eli Lilly has been a key player in the obesity drug space with Wegovy, but Novo Nordisk’s superior trial outcomes could shift perceptions and expectations regarding market dominance.
